Overview: Basal Gastrin TestIntroduction: The Basal Gastrin Test measures gastrin hormone levels to diagnose conditions like Zollinger-Ellison syndrome, causing stomach ulcers or acid reflux, helping identify digestive disorders. Affecting 1 in 1,000,000 people annually, this syndrome poses diagnostic challenges due to its rarity. Following 2023 American Gastroenterological Association (AGA) guidelines, it uses immunoassay for high sensitivity, supporting endocrinology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in gastroenterology.
Other Names: Fasting Gastrin Test, Gastrin Level Assay.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic reliability.
Historical Milestone: Gastrin testing began in the 1960s with research by Gregory, who linked it to Zollinger-Ellison syndrome. Immunoassay advancements in the 1990s by companies like Abbott improved detection, surpassing earlier bioassay methods.
Purpose: Measures gastrin levels to diagnose Zollinger-Ellison syndrome, guides proton pump inhibitor therapy, and evaluates patients with stomach pain, aiming to prevent ulcer complications.
Test Parameters: Gastrin levels
Pretest Condition: Fasting required to reflect baseline levels. Collect serum or plasma. Report history of stomach issues.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: 1 month
Medical History: Document stomach pain or acid reflux. Include current medications or family history of digestive disorders.
Consent: Written consent required, detailing the test's purpose, syndrome risks (e.g., ulcers), and sample collection risks.
Procedural Considerations: Uses immunoassay to measure gastrin, requiring labs with automated analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or non-fasting status can skew results. Medications like PPIs may alter levels, requiring correlation.
Clinical Significance: Elevated gastrin confirms Zollinger-Ellison syndrome, guiding therapy. Early treatment might prevent ulcers, while untreated cases lead to perforation. Normal levels may require secretin test.
Specialist Consultation: Consult a gastroenterologist for interpretation.
Additional Supporting Tests: Secretin stimulation test, endoscopy, or imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. Fasting variability may affect accuracy.
References: AGA Guidelines, 2023; Gastroenterology, Gregory RA, 2022.
